TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: Pharmacometabolomics-informed pharmacogenomics

Molecular Psychiatry

Volumn 21, Issue 12, 2016, Pages 1717-1725

  Gupta, M ^a   Neavin, D ^a   Liu, D ^a   Biernacka, J ^b   Hall Flavin, D ^b   Bobo, W V ^b   Frye, M A ^b   Skime, M ^b   Jenkins, G D ^b   Batzler, A ^b   Kalari, K ^b   Matson, W ^c   Bhasin, S S ^c   Zhu, H ^d   Mushiroda, T ^e   Nakamura, Y ^f   Kubo, M ^e   Wang, L ^a   Kaddurah Daouk, R ^d   Weinshilboum, R M ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e RIKEN   (Japan)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; GLUTAMATE RICH 3; GLUTAMIC ACID; PURINE; SEROTONIN; TETRASPANIN; TETRASPANIN 5; TOCOPHEROL; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; SEROTONIN UPTAKE INHIBITOR; TSPAN5 PROTEIN, HUMAN;

ARTICLE; CHROMOSOME 1; CHROMOSOME 4; CLINICAL OUTCOME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DDC GENE; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG METABOLISM; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MAOA GENE; MENTAL PATIENT; METABOLOMICS; NEUROBLASTOMA CELL LINE; PHARMACOGENOMICS; PHARMACOMETABOLOMICS; PHENOTYPE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUANTITATIVE TRAIT LOCUS; SEROTONIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; TPH1 GENE; TPH2 GENE; ADULT; BLOOD; CELL LINE; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETICS; MALE; METABOLISM; PHARMACOGENETICS; PROCEDURES; TREATMENT OUTCOME;

ADULT; CELL LINE; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; METABOLOMICS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TETRASPANINS; TREATMENT OUTCOME;

EID: 84959121708     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2016.6     Document Type: Article

References (74)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 420: 21-27
2. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011; 9: 90
3. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 2014; 13: 153-160
4. Morrissette DA, Stahl SM. Modulating the serotonin system in the treatment of major depressive disorder. CNS Spectr 2014; 19: 54-68
5. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebocontrolled trials. CNS Spectr 2002; 7(4 Suppl 1): 40-44
6. El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Blier P. Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther 2010; 16: e1-17
7. Anderson HD, Pace WD, Libby AM, West DR, Valuck RJ. Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study. Clin Ther 2012; 34: 113-123
8. Smith AJ, Sketris I, Cooke C, Gardner D, Kisely S, Tett SE. A comparison of antidepressant use in Nova Scotia, Canada and Australia. Pharmacoepidemiol Drug Saf 2008; 17: 697-706
9. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in ∗D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40
10. Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, et al. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry 2015; 5: e553
11. Ji Y, Biernacka JM, Hebbring S, Chai Y, Jenkins GD, Batzler A, et al. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J 2013; 13: 456-463
12. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157: 1552-1562
13. Bierut LJ, Heath AC, Bucholz KK, Dinwiddie SH, Madden PA, Statham DJ, et al. Major depressive disorder in a community-based twin sample: are there different genetic and environmental contributions for men and women? Arch Gen Psychiatry 1999; 56: 557-563
14. McGuffin P, Katz R, Watkins S, Rutherford J. A hospital-based twin register of the heritability of DSM-IV unipolar depression. Arch Gen Psychiatry 1996; 53: 129-136
15. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. The lifetime history of major depression in women. Reliability of diagnosis and heritability. Arch Gen Psychiatry 1993; 50: 863-870
16. Serretti A, Benedetti F, Zanardi R, Smeraldi E. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1074-1084
17. Fabbri C, Minarini A, Niitsu T, Serretti A. Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. Exp Opin Drug Metab Toxicol 2014; 10: 1093-1118
18. Laje G, Perlis RH, Rush AJ, McMahon FJ. Pharmacogenetics studies in ∗D: strengths, limitations, and results. Psychiatr Serv 2009; 60: 1446-1457
19. Myung W, Kim J, Lim SW, Shim S, Won HH, Kim S, et al. A genome-wide association study of antidepressant response in Koreans. Transl Psychiatry 2015; 5: e633
20. Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45: 183-194
21. GENDEP Investigators, MARS Investigators, ∗D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 2013; 170: 207-217
22. Tansey KE, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans D, et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 2012; 9: e1001326
23. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010; 167: 555-564
24. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010; 67: 133-138
25. Weizman S, Gonda X, Dome P, Faludi G. Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder. Neuropsychopharmacol Hung 2012; 14: 87-101
26. Fabbri C, Serretti A. Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. Curr Psychiatry Rep 2015; 17: 594
27. Singh AB, Bousman CA, Ng C, Berk M. Antidepressant pharmacogenetics. Curr Opin Psychiatry 2014; 27: 43-51
28. Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 2011; 89: 97-104
29. Abo R, Hebbring S, Ji Y, Zhu H, Zeng ZB, Batzler A, et al. Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics 2012; 22: 247-253
30. Monteiro MS, Carvalho M, Bastos ML, Guedes de Pinho P. Metabolomics analysis for biomarker discovery: advances and challenges. Curr Med Chem 2013; 20: 257-271
31. Zhu H, Bogdanov MB, Boyle SH, Matson W, Sharma S, Matson S, et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder -possible role for methoxyindole pathway. PloS One 2013; 8: e68283
32. Kaddurah-Daouk R, Bogdanov MB, Wikoff WR, Zhu H, Boyle SH, Churchill E, et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl Psychiatry 2013; 3: e223
33. Kaddurah-Daouk R, Weinshilboum R. Metabolomic signatures for drug response phenotypes: Pharmacometabolomics enables precision medicine. Clin Pharmacol Ther 2015; 98: 71-75
34. Ellero-Simatos S, Lewis JP, Georgiades A, Yerges-Armstrong LM, Beitelshees AL, Horenstein RB, et al. Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT Pharmacometrics Syst Pharmacol 2014; 3: e125
35. Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Zhu H, Lewis JP, Horenstein RB, et al. Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Thera 2013; 94: 525-532
36. Mrazek DA, Biernacka JM, McAlpine DE, Benitez J, Karpyak VM, Williams MD, et al. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study. J Clin Psychopharmacol 2014; 34: 313-317
37. Ji Y, Schaid DJ, Desta Z, Kubo M, Batzler AJ, Snyder K, et al. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol 2014; 78: 373-383
38. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013; 45: 580-585
39. Matson WR, Langlais P, Volicer L, Gamache PH, Bird E, Mark KA. n-Electrode threedimensional liquid chromatography with electrochemical detection for determination of neurotransmitters. Clin Chem 1984; 30: 1477-1488
40. Liu M, Ingle JN, Fridley BL, Buzdar AU, Robson ME, Kubo M, et al. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol 2013; 27: 657-670
41. Niu N, Qin Y, Fridley BL, Hou J, Kalari KR, Zhu M, et al. Radiation pharmacogenomics: A genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res 2010; 20: 1482-1492
42. Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, et al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 2008; 68: 7050-7058
43. Ingle JN, Liu M, Wickerham DL, Schaid DJ, Wang L, Mushiroda T, et al. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov 2013; 3: 812-825
44. Liu M, Goss PE, Ingle JN, Kubo M, Furukawa Y, Batzler A, et al. Aromatase inhibitorassociated bone fractures: a case-cohort GWAS and functional genomics. Mol Endocrinol 2014; 28: 1740-1751
45. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56-65
46. Garcia-Frigola C, Burgaya F, Calbet M, de Lecea L, Soriano E. Mouse Tspan-5, a member of the tetraspanin superfamily, is highly expressed in brain cortical structures. Neuroreport 2000; 11: 3181-3185
47. Garcia-Frigola C, Burgaya F, de Lecea L, Soriano E. Pattern of expression of the tetraspanin Tspan-5 during brain development in the mouse. Mech Dev 2001; 106: 207-212
48. Juenger H, Holst MI, Duffe K, Jankowski J, Baader SL. Tetraspanin-5 (Tm4sf9) mRNA expression parallels neuronal maturation in the cerebellum of normal and L7En-2 transgenic mice. J Comp Neurol 2005; 483: 318-328
49. Todd SC, Doctor VS, Levy S. Sequences and expression of six new members of the tetraspanin/TM4SF family. Biochim Biophys Acta 1998; 1399: 101-104
50. Ramasamy A, Trabzuni D, Guelfi S, Varghese V, Smith C, Walker R, et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. Nat Neurosci 2014; 17: 1418-1428
51. Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet 2013; 45: 1238-1243
52. Weinshilboum R, Wang L. Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity. Clin Pharmacol Ther 2004; 75: 253-258
53. Wang L, Nguyen TV, McLaughlin RW, Sikkink LA, Ramirez-Alvarado M, Weinshilboum RM. Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci USA 2005; 102: 9394-9399
54. Li F, Wang L, Burgess RJ, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation. Pharmacogenet Genomics 2008; 18: 1083-1094
55. Wang L, Sullivan W, Toft D, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 2003; 13: 555-564
56. Dunn CD, Sulis ML, Ferrando AA, Greenwald I. A conserved tetraspanin subfamily promotes Notch signaling in Caenorhabditis elegans and in human cells. Proc Natl Acad Sci USA 2010; 107: 5907-5912
57. Dornier E, Coumailleau F, Ottavi JF, Moretti J, Boucheix C, Mauduit P, et al. TspanC8 tetraspanins regulate ADAM10/Kuzbanian trafficking and promote Notch activation in flies and mammals. J Cell Biol 2012; 199: 481-496
58. Haining EJ, Yang J, Bailey RL, Khan K, Collier R, Tsai S, et al. The TspanC8 subgroup of tetraspanins interacts with A disintegrin and metalloprotease 10 (ADAM10) and regulates its maturation and cell surface expression. J Biol Chem 2012; 287: 39753-39765
59. Iwai K, Ishii M, Ohshima S, Miyatake K, Saeki Y. Expression and function of transmembrane-4 superfamily (tetraspanin) proteins in osteoclasts: reciprocal roles of Tspan-5 and NET-6 during osteoclastogenesis. Allergol Int 2007; 56: 457-463
60. Zhou J, Fujiwara T, Ye S, Li X, Zhao H. Downregulation of Notch modulators, tetraspanin 5 and 10, inhibits osteoclastogenesis in vitro. Calcif Tissue Int 2014; 95: 209-217
61. Shi M, Hu ZL, Zheng MH, Song NN, Huang Y, Zhao G, et al. Notch-Rbpj signaling is required for the development of noradrenergic neurons in the mouse locus coeruleus. J Cell Sci 2012; 125(Pt 18): 4320-4332
62. Alvarez JC, Gluck N, Fallet A, Gregoire A, Chevalier JF, Advenier C, et al. Plasma serotonin level after 1day of fluoxetine treatment: a biological predictor for antidepressant response? Psychopharmacology (Berl) 1999; 143: 97-101
63. Moreno J, Campos MG, Lara C, Lopez G, Pavon L, Hernandez ME, et al. Tryptophan and serotonin in blood and platelets of depressed patients: Effect of an antidepressant treatment. Salud Mental 2006; 29: 4
64. Urbina M, Pineda S, Pinango L, Carreira I, Lima L. [3H]Paroxetine binding to human peripheral lymphocyte membranes of patients with major depression before and after treatment with fluoxetine. Int J Immunopharmacol 1999; 21: 631-646
65. Tyrer SP, Marshall EF, Griffiths HW. The relationship between response to fluoxetine, plasma drug levels, imipramine binding to platelet membranes and whole-blood 5-HT. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 797-805
66. Hernandez ME, Mendieta D, Martinez-Fong D, Loria F, Moreno J, Estrada I, et al. Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. Eur Neuropsychopharmacol 2008; 18: 917-924
67. Blardi P, De Lalla A, Leo A, Auteri A, Iapichino S, Di Muro A, et al. Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J Clin Psychopharmacol 2002; 22: 131-136
68. Kotzailias N, Marker M, Jilma B. Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebocontrolled trial. J Clin Psychopharmacol 2004; 24: 536-539
69. Blardi P, de Lalla A, Urso R, Auteri A, Dell'Erba A, Bossini L, et al. Activity of citalopram on adenosine and serotonin circulating levels in depressed patients. J Clin Psychopharmacol 2005; 25: 262-266
70. Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J 1997; 11: 428-442
71. Kurita-Taniguchi M, Hazeki K, Murabayashi N, Fukui A, Tsuji S, Matsumoto M, et al. Molecular assembly of CD46 with CD9, alpha3-beta1 integrin and protein tyrosine phosphatase SHP-1 in human macrophages through differentiation by GM-CSF. Mol Immunol 2002; 38: 689-700
72. Claas C, Stipp CS, Hemler ME. Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J Biol Chem 2001; 276: 7974-7984
73. Kovall RA, Hendrickson WA. Crystal structure of the nuclear effector of Notch signaling, CSL, bound to DNA. EMBO J 2004; 23: 3441-3451
74. Borggrefe T, Oswald F. The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci 2009; 66: 1631-1646